SOR-C13 is a peptide antagonist of transient receptor potential vanilloid 6 (TRPV6).1 It inhibits calcium flux in HEK293 cells expressing human TRPV6 (EC50 = 14 nM). SOR-C13 (400, 600, and 800 mg/kg) reduces tumor volume in an SKOV3 ovarian cancer mouse xenograft model.WARNING This product is not for human or veterinary use.
References
[1] HUI XUE. Inhibition of Transient Receptor Potential Vanilloid 6 channel, elevated in human ovarian cancers, reduces tumour growth in a xenograft model.[J]. Journal of Cancer, 2018, 9 17: 3196-3207. DOI: 10.7150/jca.20639
